Objective Measures of ADHD Symptoms Using the Quotient(TM) ADHD System May Reduce Cost of ADHD D...(rity of scores while on placebo to those...)

Date:11/2/2009

rity of scores while on placebo to those at baseline. While it may seem intuitively obvious that objective measures would be more sensitive to treatment effects than rating scales, objective measures of response are not often used in clinical trials. With the availability of the Quotient ADHD System, may encourage drug developers to re-evaluate the potential benefit of objective measures in differentiating placebo and drug response.

About the Quotient ADHD System

The Quotient(TM) ADHD System is FDA-cleared for objective measurement of hyperactivity, impulsivity and inattention as an aid in the assessment of ADHD. The Quotient(TM) ADHD Test takes 15 minutes for children 12 and under, or 20 minutes for adolescents and adults. The report is available within a few minutes after the patient completes the test. The clinician integrates the Quotient(TM) ADHD Test report with information from other assessment tools and the clinical evaluation to guide treatment decisions. For more information about the Quotient(TM) ADHD System and case studies, please visit http://www.BioBDx.com/Products.aspx.

About BioBehavioral Diagnostics Company

BioBehavioral Diagnostics Company manufactures and markets the Quotient(TM) ADHD System, a tool that aids in the objective and accurate assessment of ADHD symptoms. We are dedicated to providing physicians, parents and patients with high-value information to guide personalized strategies and to enhance quality of life for patients with ADHD. Our vision is to provide accurate tools for the diagnosis and management of neurological and psychiatric conditions, leading to a transformation of behavioral medicine. Founded in 2006, BioBehavioral Diagnostics is a privately held company.

For more information about BioBehavioral Diagnostics, please visit www.BioBDx.com.

<
'/>"/>

SOURCE BioBehavioral Diagnostics Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Oncothyreon highlights corporate and clinical objectives for 2008
2. Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
3. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
4. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
5. AMDL, Inc. Announces 2009 Financial Guidance and First Quarter Business Objectives
6. Nile Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350 and Reiterates 2009 Objectives
7. New force-fluorescence device measures motion previously undetectable
8. APIC Statement on Need for Increased Prevention Measures for Healthcare-Associated Infections (HAIs)
9. New technique measures ultrashort laser pulses at focus
10. SpectraCell Laboratories Now Measures Vitamin C
11. NIST studies how new helium ion microscope measures up